Bristol Myers Squibb to Offer More Than 80% off Sotyktu List Price

Bristol Myers Squibb will offer Sotyktu (deucravacitinib) at more than 80% off the current list price to eligible, cash-paying U.S. patients, according to a news release published today. The current list price of Sotyktu is $6,828 for a 30-day supply.

This offer builds upon Bristol Myers Squibb’s existing offer of more than 40% off the Eliquis (apixaban) list price. The current list price is $606 for a 30-day supply.

“We are proud to now offer Sotyktu at a lower price via BMS Patient Connect, our new direct-to-patient platform designed to make our innovative medicines more accessible and affordable for patients living with serious conditions,” Christopher Boerner, Ph.D., board chair and CEO of Bristol Myers Squibb, said in the news release. “We are taking a leading role in removing barriers, providing transparency and lowering out-of-pocket costs so patients in the United States can get the treatments they need—delivered directly to their door, wherever they are in the country.”

The Sotyktu offer begins in January 2026, with shipping available across all 50 states and Puerto Rico. BMS Patient Connect will also provide patient support resources.

Sotyktu is an oral medication used to treat moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy, such as pills or injections, or phototherapy, which uses ultraviolet light. Approved by the FDA in 2022, it is still the only tyrosine kinase 2 inhibitor approved worldwide.

The Eliquis discount is already available through the Bristol Myers Squibb-Pfizer Alliance program, which launched this month. The medication is available for purchase through the Eliquis 360 Support website.

“The BMS-Pfizer Alliance is committed to increasing patient access and affordability, which is why we are launching this direct-to-patient offering for Eliquis. Eliquis is the nation’s number one prescribed oral anticoagulant that provides important benefits to patients and the healthcare system,” Christopher Boerner, Ph.D., board chair and CEO of Bristol Myers Squibb, said in a separate news release. “This program passes more savings directly to patients and demonstrates our continued focus on identifying innovative solutions that foster the best outcomes for each individual while prioritizing access to care.”

Eliquis is an oral anticoagulant medication used in children and adults to treat blood clots in the veins of the legs and lungs, also called venous thromboembolism. More than 15 million people have been prescribed Eliquis since it was first approved in 2012, resulting in more than $3 billion in total healthcare cost savings associated with hospitalizations and extended rehabilitation needs. It is not recommended for use in children who weigh less than 5.7 lbs.

These Bristol Myers Squibb announcements fit into the larger trend of direct-to-patient platforms, which are geared toward uninsured customers paying for their prescriptions in cash.

Medications are typically prescribed online during a telehealth appointment and then shipped directly to the patient. These programs have gained popularity due to surging drug prices and increased interest in a “consumer-like” healthcare experience.

Bristol Myers Squibb is the latest company to offer these discounts. Eli Lilly, Pfizer and Novo Nordisk also offer some of their drugs at a direct-to-consumer discount.